Key facts, as of
As of October 8, 2026, Amgen Inc. (AMGN) trades at $413.08, up 39.8% over the past year. Its 52-week range runs from $288.00 to $447.03; the price is 7.6% below that high. It is 7.6% below its all-time high of $447.03, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +240.5%, against +312.9% for the S&P 500 (SPY). It sits 12.9% above its 200-day average of $365.75, the usual sign of a long-term uptrend. Its 30-day volatility is 27.4% annualized, which we rate medium risk. It has a trailing P/E of 25.7 and a dividend yield of 2.44%.
Cite: Portfolio Terminal, "Amgen Inc. (AMGN) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/amgn
Where it trades today
trading 79% of the way up its 52-week range
How the price has moved
How far it is from its record
Amgen Inc. (AMGN) is 7.6% below its all-time high of $447.03, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +240.5%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- AMGN trades at 25.7x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 27.4%, above the sector norm of 22.0%, so position sizing matters more than usual.
- AMGN is in a bullish short-term regime and only 7.6% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- AMGN is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in AMGN.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for AMGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for AMGN. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Amgen Inc. does
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple…
Employees
31,500
Industry
Drug Manufacturers - General
Headquarters
Thousand Oaks, United States
What analysts expect
AMGN carries a hold consensus from 29 analysts, with an average price target of $391.46 versus $413.08 today (-5.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
AMGN generated $38.09B in trailing revenue (9.5% year over year), with a 23.0% net margin, and $8.65B of free cash flow, against $43.31B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $36.75B | $24.71B | $9.08B | $7.71B | $14.33 | $8.10B |
| 2024 | $33.42B | $20.57B | $7.26B | $4.09B | $7.62 | $10.39B |
| 2023 | $28.19B | $19.74B | $7.90B | $6.72B | $12.56 | $7.36B |
| 2022 | $26.32B | $19.92B | $9.57B | $6.55B | $12.18 | $8.79B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
AMGN is in 12 of the 30 ETFs we track. It weighs most in DIA: 4.70% of the fund, holding #4 of 30.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
AMGN beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, pressing toward $446.43 resistance.
uptrend- Price is 0.5% above its 50-day average and 12.9% above its 200-day.
- RSI at 54 is neither stretched nor washed out.
- The nearest ceiling is $446.43 (+8.1%), the nearest floor $394.65 (-4.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is AMGN a good investment in 2026?
Amgen Inc. trades at a P/E ratio of 25.7, with medium volatility (27.4% annualized). Recent momentum is positive.
What is the risk level of AMGN?
Based on 30-day volatility of 27.4%, AMGN has MEDIUM risk. Beta of 0.41 indicates lower sensitivity to market movements than average.
Does AMGN pay dividends?
Yes, Amgen Inc. has a dividend yield of 2.44%.
How far is AMGN from its all-time high?
Amgen Inc. is 7.6% below its all-time high of $447.03, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +240.5%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold AMGN?
12 of the 30 popular ETFs we track hold Amgen Inc.. The largest weights: DIA (4.70%), SCHD (3.82%), XLV (3.55%), VIG (0.99%) and QQQM (0.92%). Measured on each issuer's full holdings file, dated August 31 to October 1, 2026.
How much of VOO is AMGN?
0.35%, as of August 31, 2026: AMGN is holding #47 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $3.51 in Amgen Inc..
What is the analyst price target for AMGN?
The average analyst price target for Amgen Inc. (AMGN) is $391.46 based on 29 analyst estimates, about 5.2% below the current price of $413.08. The published range runs from $225.00 to $500.00.
How much revenue does AMGN generate?
Amgen Inc. reported $38.09B in trailing twelve-month revenue. Revenue growth is running at 9.5% year over year. Net margin sits at 23.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare AMGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.